by Richard Daverman, PhD
April 23, 2014 -- GlaxoSmithKline announced it will acquire Novartis’ (NYSE: NVS) money-losing vaccine business for $7.1 billion. That business includes manufacturing facilities in China and India. Novartis bought an 85% share of vaccine maker Zhejiang Tianyuan Bio-Pharma in 2011 for $125 million, which will transfer to GSK. GSK expects to realize about $800 million of savings once the Novartis vaccine business is fully integrated. More details....
Stock Symbol: (NYSE: GSK)
Help employers find you! Check out all the jobs and post your resume.
